Abemaciclib
CDK inhibitor
Abemaciclib, sold under the brand name Verzenio among others, is a medication for the treatment of advanced or metastatic breast cancers. It was developed by Eli Lilly and it acts as a CDK inhibitor selective for CDK4 and CDK6.
Nº Q23901483 ★
Common · Knowledge
Abemaciclib
CDK inhibitor
Abemaciclib, sold under the brand name Verzenio among others, is a medication for the treatment of advanced or metastatic breast cancers. It was developed by Eli Lilly and it acts as a CDK inhibitor selective for CDK4 and CDK6.
Last price
—
Floor price
—
7-day median
—
30-day sales
0
30-day range
—
In circulation
0
Price history
median
low – high
sales
No sales in this period
Show table
| Date | median | Low | High | sales |
|---|
Sales history
- Last sale
- —
- 30-day average
- —
- 30-day low
- —
- 30-day high
- —
- Sales 7d
- 0
- Sales 30d
- 0
No sales yet.
Anonymous sales: no buyer or seller shown. Figures count player-to-player sales only.
From Wikipedia
Abemaciclib, sold under the brand name Verzenio among others, is a medication for the treatment of advanced or metastatic breast cancers. It was developed by Eli Lilly and it acts as a CDK inhibitor selective for CDK4 and CDK6. It was designated as a breakthrough therapy for breast cancer by the US Food and Drug Administration (FDA) in October 2015. In September 2017, it was approved for use in the United States by the FDA for the treatment of certain breast cancers.
Text: Wikipédia, CC BY-SA 4.0. · Image: Ed (Edgar181) (Public domain) ·
Related cards
-
Amivantamab
Medication
Nº Q106957199 ★
Not listed
-
Olaparib
Chemical compound (cancer therapy drug)
Nº Q7083106 ★
Not listed
-
Cetuximab
Pharmaceutical drug
Nº Q420296 ★
Not listed
-
Upadacitinib
Chemical compound
Nº Q27074125 ★★
Not listed
-
Tamoxifen
Chemical compound
Nº Q412178 ★★★
Not listed
-
Adalimumab
Pharmaceutical drug
Nº Q348260 ★★★
Not listed